FCM
TPST icon

Flinton Capital Management’s Tempest Therapeutics TPST Stock Holding History

Flinton Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed -$2K – 907
2018
Q3 		$2K Buy
+1
New +$2.4K ﹤0.01% 861

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $871M AUM 27.72% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Flinton Capital Management's TPST Position: Q4 2018 in Review

Flinton Capital Management sold out of Tempest Therapeutics (TPST) in Q4 2018, closing a stake of 1 share — an estimated $2K sold.

Flinton Capital Management first reported a position in TPST in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 30 funds tracked by Wall St. Rank hold TPST as of Q4 2018.

  • Flinton Capital Management reported no remaining Tempest Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Flinton Capital Management sold 1 Tempest Therapeutics share in Q4 2018, an estimated $2K.
  • Flinton Capital Management first reported a position in Tempest Therapeutics in Q3 2018 and held it in 1 quarter.
  • Flinton Capital Management's Tempest Therapeutics position peaked at $2K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2018.

Based on Flinton Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.